Deals
Bridgepoint to Ask JPMorgan to Advise on Diaverum Future
This article is for subscribers only.
Bridgepoint Advisers Ltd., a U.K. private-equity firm with more than $12 billion in committed funds, will choose JPMorgan Chase & Co. to consider Swedish renal-care provider Diaverum’s future.
Bridgepoint “is close” to completing JPMorgan’s appointment to look at strategic options for Lund-based Diaverum for the next 12 months, James Murray, a spokesman for the firm, said by phone today.